Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Clone 3 is a cure in that it is a MAB that attaches to an immutable site on the virus. They’ve found more than one site. They will be creating multiple MABS that attach to the other immutable sites to make a cocktail.
Nice update on patents.
$ENZC @enzolytics IP portfolio is on 🔥. #ScienceWillWin
— King of Prussia (@ImKingofPrussia) August 10, 2023
Box 1: Covid patent EP phase.
Box 2: 1st HIV Patent EP phase.
Box 3: 2nd HIV Patent notifies of EP intent.
Box 4: IPF Immune trademark coming soon. pic.twitter.com/6RfBkkT0GG
Previous trials from ~2015.
“Currently, the Company is working with European Medicines Agency (EMA) consultants in marshaling the extensive prior clinical trial and technical data for application in advancing this therapeutic under the EMA for approval for use in European Union countries.”
https://enzolytics.com/company-news/
ITV-1 was already further along in trials. They used previous data to basically start where they left off.
ITV-1 was always going to be quicker to market. That fact is why I invested here initially.
Gotcha, I thought the thread was referencing the HIV and COV19.
Priority dates are Feb and Mar of 2021. They’re farther along than 14 and 16 months.
Exactly.
We’re getting the tech we’ve all been excited about, with a better share structure, on an exchange that will open more doors for us.
Sometimes I think they are just auto replies. Exact same thing repeated over and over.
Zhabilov has nothing to do with Clone 3.
RobustoMed will be initiating a new business model focused on developing international partnership opportunities for medical development stage drug and product companies.
https://www.accesswire.com/656951/Enzolytics-Announces-the-Appointment-of-Steve-Sharabura-as-President-of-its-Wholly-Owned-Subsidiary-RobustoMed-Inc-AKA-ENZO-SUB
The Company continues to explore the spin-out opportunities with RobustoMed, Inc.
https://enzolytics.com/company-news/
For me it’s more about those that have been bitching about everything all the time. Say they’re faithful longs and bitch the whole time. I believe everyone will benefit greatly down the road, those with larger positions obviously more.
Never said it was approved. They’re about to start the trials again through EMA. After what should be positive results, the hope is to get approved through EMA. Then get reciprocity through FDA as I said earlier.
They’ll probably go the EMA route like with ITV-1. Then get reciprocity with FDA. Likely easier, probably cheaper route. Sounds like a win win to me.
I have to disagree, I think the progress with clinical trials for diabetic treatment is a pretty big step.
The insurance and all permits being paid for is nice to see as well. I agree on hoping the protocol doesn’t drag out, but I definitely wouldn’t say the entire PR was nonsense and irrelevant.
You have no way of knowing the details of the deal anymore than anyone else. You can look into what BEGN and VIRO are all about on your own, which I know you already know.
They’re working on full reporting per their PR’s, we can’t know anything beyond that.
Yes the trust owns the patents, no one has argued that to my knowledge. I guess your argument would be, what if the trust pulled the licensing agreements from ENZC. To what end would that serve? It would help no one, not even the “evil insiders”.
It’s just been regurgitating the same crap for weeks. We’ll be more than okay when everything comes together.
Nice try at dancing around the question. I asked directly, do you have proof that they’re being dishonest.
I suppose you have proof of the possibility of suspension? Sounds awfully false and misleading as well.
Almost sounds like you’re saying Enzolytics management deregistered their stock from reporting.
I don’t mean that necessarily. I was going more towards maybe they can’t get insurance policies until everything is set in place.
As I said, I’m sure insurance regulations for these things are more stringent and have to meet certain criteria.
Again, completely a guess. I haven’t been able to find much on that yet.
Purely my assumption, but maybe they didn’t know when they would be able to start 100%.
You wouldn’t pay for insurance on your car until you knew you had a driver’s license.
I would assume clinical insurance is much more regulated and has strict policy dates.
Clinical Trials Insurance
All Clinical Research Sites (CRSs), where required by country regulation or law, must have secured clinical trials insurance for every new and ongoing clinical trial sponsored by DAIDS to ensure compliance with the European Medicines Agency Committee for Proprietary Medicinal Products, Art 5.8 CPMP/ICH/135/95 and the Integrated Addendum to ICH (E6) (R1): Guideline for Good Clinical Practice E6 (R2) regarding Investigator/Institution insurance against trial related claims.
Kenya and South Africa are two countries ITV-1 will be tested in that require it.
https://rsc.niaid.nih.gov/networks-protocol-teams/clinical-trials-insurance#:~:text=All%20Clinical%20Research%20Sites%20%28CRSs%29%2C%20where%20required%20by,%28R2%29%20regarding%20Investigator%2FInstitution%20insurance%20against%20trial%20related%20claims.
They clearly told us ITV-1 will be tested in Africa. I don’t understand how this is baffling people.
Enzolytics Announces the International Patent Office Search Report finding Novelty and Inventiveness in the Company’s Pending International Patent Application Covering its anti-HIV Monoclonal Antibodies.
COLLEGE STATION, TX / ACCESSWIRE / July 28, 2022 / Enzolytics, Inc.
https://enzolytics.com/company-news/
I’m aware we’re waiting on them to be granted, thought you were privy to that. You asked where we were, we are awaiting patents to be granted.
The Company has clarified the lack of significance of the prior expired Company patents covering the Company's "parent" Clone 3 anti-HIV antibody. The expired Company patents were issued on the "parent" Clone 3 antibody. As is the case with virtually all parent antibodies, the parent antibody is a "slow producer" - which means it could not produce sufficient antibody therapeutics to treat the 36 million individuals infected with HIV. Thus, a recombinant form of the antibody had to be created employing a fast-producing CHO cell line. This has been accomplished by the Company and patent applications are pending claiming the recombinant form of the antibody, the form that will be used in patient therapy. The term of issued patents will be 20 years from filings, such filings having been made in 2020.
https://www.nasdaq.com/press-release/enzolytics-announces-the-discovery-and-patenting-of-eleven-newly-identified-conserved#:~:text=The%20Company%20has%20clarified%20the%20lack%20of%20significance,were%20issued%20on%20the%20%22parent%22%20Clone%203%20antibody.
Upon completion of the second-phase toxicology studies, the Company expects to be able to make the ITV-1 therapeutic available in countries in African countries, where the HIV pandemic is severe, namely Rwanda, the Democratic Republic of Congo, Angola, Kenya, and South Africa.
https://enzolytics.com/company-news/
Not vague at all.
Yeah but I still think we come out smelling like roses in the end. I just try to ignore it all and stay busy at work. I don’t foresee anything falling through so I TRY not to get worked up too much.
Never mind, I see that’s a different issuer at the bottom.
Pretty sure I saw 2022 as well if you expand the image from Twitter.
Pink
Very nice. Wish the SS was better, but should still make a decent move depending on the incoming entity.
Yeah curious to see who/what is coming in.
The Company expects to close a deal with a new operating partner in the second half of 2023.
From the updated company profile.
Along with the next sentence, “VIRO expects ITV-1 to be dispensed under the trial in late July / early August 2023.”
?? $FBEC
??0.0002
Expert Market, AS: 7.0B, OS: 5.9B, US: 5.5B
Business Description Updated:
?? FBEC Worldwide, Inc. is a lifestyle Brand Company with a focus on Healthy Hemp & CBD infused consumer products, both domestic and abroad. We are committed to increasing our market size and scope through the optics of creative marketing and most importantly customer satisfaction. Our growth strategies focus on a number of major initiatives, including unique branding opportunities that will be targeted at key demographic groups and to develop strong community and distributor relationships. FBEC Worldwide is currently developing and building Healthy Hemp & CBD infused consumer products, focused on strong rates of growth within key fundamental consumer groups. Our company is dedicated to becoming the lead developer of name brand hemp & CBD infused consumer products.
?? FBEC Worldwide, Inc. is being restructured and is currently seeking an operating partner. The Company expects to close a deal with a new operating partner in the second half of 2023.
Officer(s) Removed:
??Nairobi Lorean Anderson, CEO
??Nikki Lee, Other
??Profile is now Verified
Product Services Description Added.
?? The Company is seeking an operating partner and currently offers no products of services.
Facilities Description Added.
?? Shared professional office space located in Sugar Land, Texas.
Chart, OTC Profile, Twitter, @otcupdates
Update: 2023-06-05 20:15:20 (UTC)
I feel like I’m the only one who saw that. No one is talking about it.
Just have to wait for the pps to increase and everyone will be happy again.
https://www.lifesciencesreview.com/about-us/
PR stated we’ll be featured in the June issue.